The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...

LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...

Doctors suggest that anybody with a Body mass index of over 30 or greater than 27 is advised to try weight loss drugs.

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 medications.